Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mosman terminates drilling at Colorado helium project

(Sharecast News) - Helium, hydrogen and hydrocarbon explorer Mosman saw its share price drop 10% on Thursday after the AIM-listed group stopped drilling at the part-owned Vecta Helium Project following disappointing initial results. The company said that the drilling campaign at the Colorado project, which was targeting the helium-rich Lyons formation at depths of 1,200-1,500 feet, has now been terminated after results from the first three wells were not as expected.

The total cost of the drilling so far was just under $215,000, and with the remaining two planned wells incurring no cost to Mosman, it was able to exist the programme "with minimal financial impact and no further payments". Mosman has a 20% working interest at the project.

"The Lyons formation, a Permian-aged sandstone reservoir, typically contains helium percentages of 2-3%, with historical highs up to 11%. However, the low-pressure gas (below 40 psi) and resultant low flow rates require high helium concentrations to justify the extensive development wells needed for commercial viability," the company explained in a statement.

"Mosman's decision to exit the project reflects a strategic move to limit exposure in a high-risk exploration area."

Shares were down 10.2% at 0.022p by 1141 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.